title: Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?
authors.affiliation: City of Hope Comprehensive Cancer Center, Duarte, CA, USA. kreckamp@coh.org
authors.forename: Karen L
authors.initials: KL
authors.lastname: Reckamp
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib